Description:

This lecture will outline and describe the current understanding of thyroid eye disease (TED) and its interrelation with Graves' Disease.  It will describe incidence, risk factors, and associated systemic signs, symptoms, and pathophysiology including Rundle's curve.  We will discuss treatment options for TED including the recent FDA approval of Teprotumumab, its clinical trials, study endpoints, and adverse reactions.  Masquerading ocular findings that may be early signs of TED will be described as well as lab testing that can help with the early detection of TED will be discussed.  Doctors have a knowledge need for this practice gap which means having the knowledge of how to detect, diagnose, and treat TED in an integrated, multidisciplinary method.

Course Code:

AOA363-SD

Speaker(s):

Jacob Lang, O.D.

drjakelang@gmail.com

Selina McGee, O.D.

drmcgee@bespokevision.org

Credits:

1

AOA Expiration Date:

12/7/2025

Related News

'All the advocacy firepower’ called up at AOA on Capitol Hill

Over 500 AOA doctors and optometry students championed the profession’s priority issues in Washington, D.C., including a growing Congressional focus on vision plan abuses.

Build your practice and protect the planet

Every day is Earth Day at these optometric practices. Considerations for an environmentally friendly practice.

Intentional leadership

The AOA’s 2023 Young Optometrist of the Year is a leader—and she has been intentional in cultivating those skills. Uncover her philosophy on leadership.